Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $22.2852W HIGH $254.48
Volume
9.02 M
Value Traded
371.75 M
Short % Float
8.93%
Days to Cover
1.8
+10.8%Week
+15.14%1 Month
+304.45%3 Month
+388.69%6 Month
-72.25%5 Year
+113.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
88.52 B
EPS (TTM)
-7.89
P/E Ratio
-
Ent. Value
82.20 B
Total Shares
399.24 M
Float Shares
365.20 M
Insiders
8.52%
Institutions
80.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MRNA Catalyst Timeline
Dated clinical, regulatory and corporate events for Moderna, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Moderna, Inc.
451Total events
10Upcoming
168Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Primary Endpoint Metintismeran autogeneClinical Data
INTerpath-001 met primary endpoint of recurrence-free survival
completely resected stage IIB–IV melanomasource ↗
▲Topline Readoutintismeran autogeneClinical Data
Positive topline results from Phase 3 INTerpath-001 with intismeran autogene plus KEYTRUDA
resected stage IIB-IV melanomasource ↗
▲FDA ApprovalmFLUSIVAApprovedFDA Decision
mFLUSIVA approved by FDA for seasonal influenza
seasonal influenzasource ↗
▲FDA ApprovalmCOMBRIAXApprovedFDA Decision
EU approval of mCOMBRIAX (flu + COVID combination vaccine)
Flu + COVID combinationsource ↗
▲FDA ApprovalmRESVIAApprovedFDA Decision
EU approval of mRESVIA for all individuals aged 18 and older
RSVsource ↗
▲Trial Initiationintismeran autogeneTrial
Initiated Phase 3 study of intismeran autogene as monotherapy and in combination with KEYTRUDA QLEX for high-risk Stage 1 NSCLC
high-risk Stage 1 non-small cell lung cancersource ↗
▲Trial InitiationmRNA-1018Trial
Initiation of Phase 3 study of mRNA-1018 pandemic influenza vaccine
pandemic influenzasource ↗
●Oral PresentationmRNA-1083FiledPresentation
Presented mRNA-1083 data from Japanese cohort at ESCMID 2026
flu + COVID combinationsource ↗
●Oral PresentationmRNA-1010ApprovedPresentation
Presented mRNA-1010 revaccination data at ESCMID 2026
seasonal flusource ↗
▲Partnership / LicenseCorporate
Settlement agreement with Arbutus Biopharma and Genevant Sciences resolving all litigation worldwide
◆Oral PresentationmRNA-1010ApprovedPresentation
Late-breaking oral presentation on revaccination data for mRNA-1010 at ESCMID 2026
seasonal influenzasource ↗
◆Oral PresentationmRNA-1345ApprovedPresentation
Late-breaking oral presentation on revaccination data for mRESVIA (mRNA-1345) at ESCMID 2026
RSVsource ↗
▲EU ApprovalmCOMBRIAXApprovedEx-US Regulatory
mCOMBRIAX granted EU marketing authorization
prevention of influenza disease and COVID-19 caused by SARS-CoV-2source ↗
▲CHMP Positive OpinionmCOMBRIAXApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorization for mCOMBRIAX
influenza and COVID-19source ↗
▲Type A MeetingmRNA-1010ApprovedFDA Meeting
Type A meeting with FDA regarding mRNA-1010 BLA
seasonal influenzasource ↗
▲FDA Filing AcceptedmRNA-1010ApprovedRegulatory Filing
FDA accepted BLA for mRNA-1010 for review
seasonal influenzasource ↗
●BLA SubmissionmRNA-1010ApprovedRegulatory Filing
BLA submission for mRNA-1010 (amended application)
seasonal influenzasource ↗
▲Other Regulator MilestonemRNA-1010ApprovedEx-US Regulatory
Regulatory submissions accepted in Europe, Canada, Australia
seasonal influenzasource ↗
▲EU ApprovalmNEXSPIKEApprovedEx-US Regulatory
European Commission grants marketing authorization for mNEXSPIKE
COVID-19source ↗
▲CHMP Positive OpinionmNEXSPIKEApprovedEx-US Regulatory
CHMP positive opinion for mNEXSPIKE
COVID-19source ↗
▲Full ResultsmNEXSPIKEApprovedClinical Data
Phase 3 trial results supporting mNEXSPIKE efficacy and safety
COVID-19source ↗
▲FDA ApprovalmNEXSPIKEApprovedFDA Decision
Regulatory approval in U.S., Canada, and Australia
COVID-19source ↗
▲FDA Filing AcceptedmRNA-1010ApprovedRegulatory Filing
Regulatory filing accepted for review in EU, Canada, Australia
seasonal flusource ↗
▼Refuse To FilemRNA-1010ApprovedRegulatory Filing
Received Refusal-to-File letter from U.S. FDA
seasonal flusource ↗
●Type A MeetingmRNA-1010ApprovedFDA Meeting
Requested Type A meeting with U.S. FDA
seasonal flusource ↗
▲Enrollment CompletemRNA-4157Trial
Phase 2 adjuvant muscle invasive bladder cancer trial fully enrolled
muscle invasive bladder cancersource ↗
▲Full ResultsmRNA-4157Clinical Data
Positive five-year Phase 2b adjuvant melanoma data announced
melanomasource ↗
▲Enrollment MilestonemRNA-3927Trial
Target enrollment reached for registrational study
propionic acidemiasource ↗
▲FDA Feedback ReceivedmRNA-3705FDA Meeting
Selected by FDA for START pilot program
methylmalonic acidemiasource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Recordati for propionic acidemia candidate
▲FDA ApprovalmNEXSPIKEApprovedFDA Decision
Regulatory approvals in Canada and Australia for mNEXSPIKE
COVID-19source ↗
▲FDA ApprovalmRNA-1273ApprovedFDA Decision
Strain-updated Spikevax authorized in UK for spring vaccination campaign
COVID-19source ↗
●FDA Filing AcceptedmRNA-1083FiledRegulatory Filing
Regulatory filing under review in Europe and Canada
seasonal flu + COVIDsource ↗
▼Refuse To FilemRNA-1010ApprovedRegulatory Filing
FDA issues Refusal-to-File letter for mRNA-1010 BLA
seasonal influenzasource ↗
▲Partnership / LicenseCorporate
Signed MoU for long-term strategic agreement with Mexican Government, BIRMEX, and Liomont
▲FDA ApprovalFDA Decision
COFEPRIS approval of Moderna's 2025-2026 COVID-19 vaccine for individuals aged 6 months and older
COVID-19source ↗
▲Product LaunchPost-Market
Purchase adjudication for supply of up to 10 million doses of 2025-2026 COVID-19 vaccine to Medistik
COVID-19source ↗
Past FDA Catalysts and PDUFA Decisions
How MRNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-23 | intismeran autogene (intismeran; V940/mRNA-4157) + KEYTRUDA (pembrolizumab) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
30
Drugs Scored
rNPV / MCap
Top Drug
Top 2%
Large Pharma(rank 14 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| COVID-19 | |||
| RSV |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| mRNA-1403 VaccineNCT06592794 | Acute Gastroenteritis | Phase 3 | ACTIVE NOT_RECRUITING | 37,864 | Feb 15, 2027 | ||||||
| mRNA-1018-H5 VaccineNCT07496450 | Influenza | Phase 3 | ACTIVE NOT_RECRUITING | 4,050 | Jan 28, 2027 | ||||||
| mRNA-1195 VaccineNCT06735248 | Multiple Sclerosis | Phase 2 | RECRUITING | 180 | Jan 8, 2029 | ||||||
| mRNA-1195.1 VaccineNCT05831111 | Epstein-Barr Virus Infection | Phase 1 | ACTIVE NOT_RECRUITING | 482 | Oct 13, 2026 | ||||||
| mRNA-4157 RNA therapyNCT03897881 | Melanoma | Phase 2 | ACTIVE NOT_RECRUITING | 267 | Nov 21, 2032 | ||||||
| mRNA-4157 RNA therapyNCT03313778 | Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 161 | Nov 21, 2027 | ||||||
| mRNA-2808 RNA therapyNCT07116616 | Relapsed or Refractory Multiple Myeloma | Phase 1 | RECRUITING | 190 | Jun 17, 2032 | ||||||
| mRNA-1365 VaccineNCT07764237 | Respiratory Syncytial Virus (RSV) | Phase 1 | RECRUITING | 375 | Jul 20, 2027 | ||||||
| mRNA-1469 VaccineNCT07737717 | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Phase 1 | ACTIVE NOT_RECRUITING | 84 | Sep 30, 2027 | ||||||
| mRNA-4359 RNA therapyNCT05533697 | Advanced Solid Tumors | Phase 1 | RECRUITING | 361 | Feb 18, 2032 | ||||||
| mRNA-1982 VaccineNCT07561294 | Lyme Disease | Phase 2 | ACTIVE NOT_RECRUITING | 366 | Nov 9, 2028 | ||||||
| mRNA-4106 RNA therapyNCT06880549 | Advanced Solid Tumors | Phase 1 | RECRUITING | 42 | Aug 3, 2027 | ||||||
| mRNA-1189 VaccineNCT07478952 | Epstein-Barr Virus | Phase 1 | RECRUITING | 120 | May 15, 2027 | ||||||
| mRNA-1189 VaccineNCT05164094 | Epstein-Barr Virus Infection | Phase 1 | ACTIVE NOT_RECRUITING | 867 | Aug 18, 2027 | ||||||
| mRNA-1647 VaccineNCT05683457 | Cytomegalovirus Infection | Phase 2 | ACTIVE NOT_RECRUITING | 724 | Mar 6, 2027 | ||||||
| mRNA-3745 RNA therapyNCT05095727 | Glycogen Storage Disease | Phase 1 | ACTIVE NOT_RECRUITING | 15 | Nov 30, 2026 | ||||||
| mRNA-3705 RNA therapyNCT05295433 | Methylmalonic Acidemia | Phase 1 | RECRUITING | 56 | Apr 2, 2034 | ||||||
| mRNA-3927 RNA therapyNCT05130437 | Propionic Acidemia | Phase 1 | RECRUITING | 127 | Dec 4, 2031 | ||||||
| mRNA-1345 VaccineMarketedNCT05743881 | Respiratory Syncytial Virus | Phase 3 | ACTIVE NOT_RECRUITING | 45,237 | Aug 31, 2029 | ||||||
| mRNA-1083 VaccineCompletedNCT06694389 | COVID-19 | Phase 3 | COMPLETED | 2,457 | Nov 17, 2025 | ||||||
| mRNA-1083 VaccineCompletedNCT06097273 | SARS-CoV-2 | Phase 3 | COMPLETED | 8,061 | May 28, 2024 | ||||||
| mRNA-1083 VaccineCompletedNCT06508320 | Influenza | Phase 2 | COMPLETED | 931 | Sep 25, 2025 | ||||||
| mRNA-1083 Composition 1 Dose A Lot A VaccineCompletedNCT06864143 | Influenza | Phase 2 | COMPLETED | 1,320 | Oct 13, 2025 | ||||||
| mRNA-1083.1 VaccineCompletedNCT05827926 | SARS-CoV-2 | Phase 1 | COMPLETED | 1,758 | Dec 3, 2024 | ||||||
| mRNA-1403 VaccineCompletedNCT05992935 | Norovirus Acute Gastroenteritis | Phase 1 | COMPLETED | 1,407 | Oct 7, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MRNA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hoge StephenOfficer (President) | Option | 76,452 1,675,710 held | $12.21 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MRNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.3 % | 5.25 M | 75.00 K |
MRNA Institutional Ownership Trends
MRNA Short Interest
Shares sold short, counted twice a month.
8.93%
Short % of Float
of tradable shares sold short
32.6M
Shares Sold Short
+5.6% vs prior count
1.8 Low
Days to Cover
trading days of normal volume to buy every short share back
18.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MRNA ranks across every disease it competes in
Competitive Position is a premium feature
See how MRNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMRNA News
MRNAModerna Named a Top Employer by Science for Twelfth Consecutive Year
Moderna has been named a top employer in the biopharmaceutical industry for the twelfth consecutive year, according to Science's 2026 Top Employers Survey. The company was acknowledged for its strong corporate image and commitment to innovation. In 2026, Moderna also received approvals for two new vaccines and reported positive results from a Phase 3 cancer therapy trial.
Read more →MRNAModerna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
Moderna, Inc. will report its third quarter 2026 financial results on November 6, 2026, during a live conference call at 8:00 a.m. ET. The event will also provide a corporate update. A webcast of the call will be available on Moderna's website, with an archived version accessible for one year.
Read more →MRNA▼ -5.4%on this news
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Moderna has appointed Juan Andres as Chief Operating Officer to enhance its operational capabilities as the company expands into oncology and prepares for the launch of intismeran autogene. This strategic move follows positive Phase 3 results and the recent approval of its seasonal flu vaccine. Jerh Collins is retiring after four years, leaving a strong legacy in technical operations.
Read more →MRNA▲ +12.3%on this news· ran to +26% by day 3
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Moderna has announced that three abstracts on intismeran autogene, an investigational mRNA-based therapy, will be presented at the ESMO Congress 2026 in Madrid. This therapy targets patients with resected stage IIB-IV melanoma. Additionally, Moderna will host a live investor event on October 24 to discuss these findings.
Read more →MRNA▲ +9.9%on this news
Moderna to Present at Upcoming Conferences in September 2026
Moderna, Inc. announced its participation in two upcoming investor conferences in September 2026. The conferences include the Morgan Stanley 24th Annual Global Healthcare Conference and the Bernstein Insights Healthcare Forum. Live webcasts will be available, and replays will be archived on Moderna's website. This highlights Moderna's ongoing commitment to mRNA medicine.
Read more →MRNA▲ +9.9%on this newsshared move
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Moderna has announced the pricing of an upsized $2.6 billion offering of convertible senior notes due in 2032. The offering, initially set at $2.0 billion, will close on September 1, 2026. Proceeds will be used for general corporate purposes, including investments in oncology and debt repayment. The notes will be convertible under certain conditions.
Read more →MRNAModerna and Merck Cancer Vaccine Success Is Good News for CancerVax
CancerVax, Inc. has welcomed the positive results from Moderna and Merck's Phase 3 trial of a personalized cancer vaccine for melanoma. The trial demonstrated the effectiveness of mRNA technology in mobilizing the immune system against cancer. CancerVax's approach differs by developing a universal cancer vaccine that leverages existing immunity, potentially simplifying treatment and reducing costs.
Read more →MRNA▼ -5.4%on this news
Moderna Recognized by TIME as One of the World’s Most Impactful Companies
Moderna, Inc. has been recognized as the top company on TIME's 2026 list of the World's Most Impactful Companies, highlighting its advancements in mRNA technology and commitment to addressing significant health needs. CEO Stéphane Bancel emphasized the company's focus on innovative medicines and pandemic preparedness. Additionally, Moderna's recent approval for its flu and COVID combination vaccine marks a significant milestone in its product offerings.
Read more →MRNAModerna Reports First Quarter 2026 Financial Results and Provides Business Updates
Moderna, Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $0.4 billion, driven significantly by international markets. Despite the strong revenue growth, the company faced a net loss of $(1.3) billion, largely due to a litigation settlement expense of $0.9 billion. Key progress included the approval of its combination flu and COVID vaccine in Europe, alongside the initiation of a Phase 3 trial for intismeran in treating high-risk Stage 1 non-small cell lung cancer. Management remains optimistic about future revenue growth and additional regulatory approvals.
Read more →MRNAModerna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Moderna, Inc. will present late-breaking data on its investigational seasonal influenza vaccine, mRNA-1010, and its RSV vaccine, mRESVIA, at the ESCMID 2026 Global Congress. The studies indicate that mRNA-1010 is safe and effective for older adults, while mRESVIA shows promise for revaccination. Both vaccines are under regulatory review in several countries.
Read more →MRNAEuropean Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
Moderna's mCOMBRIAX, a combination vaccine for influenza and COVID-19, has received a positive opinion from the EMA's CHMP, marking a significant advancement in respiratory virus vaccination. This recommendation is based on successful Phase 3 trial results, indicating strong immune responses. The final marketing authorization will be decided by the European Commission.
Read more →MRNA▲ +6.7%on this news
Moderna to Present at Upcoming Conferences in March 2026
Moderna, Inc. has announced its participation in two upcoming investor conferences in March 2026. The TD Cowen 46th Annual Healthcare Conference will take place on March 3, while the Barclays 28th Annual Global Healthcare Conference is scheduled for March 10. Both presentations will be available via live webcast and archived for 30 days on Moderna's website.
Read more →MRNA▲ +6.1%on this newsshared move
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Moderna's investigational seasonal influenza vaccine, mRNA-1010, has been accepted for review by the FDA following a Type A meeting. The company aims for full approval for adults aged 50 to 64 and accelerated approval for those 65 and older. The PDUFA goal date is set for August 5, 2026, with potential availability for the upcoming flu season.
Read more →MRNAModerna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
Moderna has received marketing authorization from the European Commission for its COVID-19 vaccine mNEXSPIKE, aimed at individuals aged 12 and older. This marks the third vaccine authorized for Moderna in the EU, following Spikevax and mRESVIA. The authorization is based on positive Phase 3 trial results, showing mNEXSPIKE's efficacy and a favorable safety profile.
Read more →MRNA▲ +5.3%on this news· ran to +24% by day 3shared move
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Moderna reported its fourth quarter and full-year 2025 financial results, revealing a net loss of $2.8 billion and a 40% revenue decrease year-over-year. Despite these challenges, the company plans to achieve up to 10% revenue growth in 2026, supported by new product launches and strategic partnerships. Key updates include the full enrollment of clinical trials for Norovirus and muscle invasive bladder cancer, alongside ongoing regulatory reviews for its influenza vaccine.
Read more →MRNAModerna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Moderna announced that the FDA has issued a Refusal-to-File letter for its investigational influenza vaccine mRNA-1010, citing the choice of a licensed standard-dose vaccine comparator as the reason. The company plans to request a Type A meeting with the FDA to clarify the decision, which contradicts prior communications. Despite this setback, mRNA-1010 is under review in other countries, and Moderna does not anticipate any financial impact for 2026.
Read more →MRNAModerna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Moderna has signed a Memorandum of Understanding with the Mexican Government and local partners to establish a long-term strategic agreement. This five-year collaboration aims to enhance Mexico's health security by providing access to Moderna's respiratory vaccine portfolio and facilitating technology transfer for local manufacturing of its COVID-19 vaccine. The initiative aligns with Mexico's 'Plan Mexico' to boost local production capacity and pandemic preparedness.
Read more →MRNA▼ -6%on this newsshared move
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna has announced a strategic collaboration with Recordati to advance its investigational therapeutic mRNA-3927 for propionic acidemia. Under the agreement, Moderna will lead clinical development while Recordati will handle global commercialization. The collaboration includes up to $160 million in payments and milestones, with a pivotal data readout expected in 2026. Propionic acidemia is a rare metabolic disorder with no current disease-modifying treatments.
Read more →MRNA▼ -5.3%on this newsshared move
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
Moderna, Inc. will host a live conference call on February 13, 2026, to discuss its fourth quarter 2025 financial results and provide a corporate update. The call will be accessible via a webcast on the company's website. An archived version of the call will be available for one year post-event.
Read more →MRNAModerna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna and Merck have reported five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, showing that the combination of intismeran autogene and KEYTRUDA significantly reduces the risk of recurrence or death in patients with high-risk stage III/IV melanoma. The treatment demonstrated a 49% reduction in risk compared to KEYTRUDA alone. Further data will be presented at an upcoming medical conference, highlighting the potential of mRNA therapies in cancer care.
Read more →About Moderna, Inc.
Headquarters325 BINNEY STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next MRNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime